PMC:7102556 / 18673-18856
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 329 | 102-111 | Species | denotes | 2019-nCoV | Tax:2697049 |
| 331 | 35-53 | Disease | denotes | SARS-CoV infection | MESH:C000657245 |
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T95 | 0-10 | Body_part | denotes | Antibodies | http://purl.org/sig/ont/fma/fma62871 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T70 | 35-53 | Disease | denotes | SARS-CoV infection | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T71 | 44-53 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T117 | 0-183 | Sentence | denotes | Antibodies effective at inhibiting SARS-CoV infection should also have the potential for treatment of 2019-nCoV as well, as long as the binding motif in RBD shares the same sequences. |